Dr Reddy’s Laboratories announced the successful completion of a GMP inspection by the USFDA at its API manufacturing facility (CTO-2) in Bollaram, Hyderabad.
The inspection was carried out between November 13 and November 19, 2024. Following the inspection, the USFDA issued a Form 483 containing seven observations. Dr Reddy’s has committed to addressing the identified observations within the prescribed timeline. The company aims to ensure compliance with all regulatory requirements to maintain its operational standards.
In the National Stock Exchange, shares of Dr Reddy’s Laboratories closed at ₹1192.80 which is a 1.70% dip than the previous close. Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
